Global Ovarian Cancer Drugs Market Outlook To 2025: Key Disease Type (Epithelial Ovarian Tumors, Ovarian Germ Cell Tumors, Ovarian Stromal Tumors, Primary Peritoneal Carcinoma), Treatment Categories (Chemotherapy, Radiation therapy, Immunotherapy, Autologous stem-cell transplantation, Targeted Therapy), Drug Class (PARP inhibitors, PD-L1, Angiogenesis Inhibitors, Others), Distribution Channel (Hospitals, Drug Store, Specialty Pharmacy, E-Pharmacy), Regional Segmentation, Competitive Dynamics, M&A Insights, Pricing Analysis (OPP, IPP, RAP), And Segment Forecast

$5,650.00$12,650.00

Clear
  • Report Description
  • Table of Content
  • Highlight
  • Research Methodology
  • Request Free Sample

The global ovarian cancer drugs market was valued at $1.8 Billion in 2017 and is forecast to grow at a modest 29.2 % CAGR between 2018 and 2025, culminating in 2025 global sales of $X.5 Billion.

 

Ovarian cancer is a group of diseases that originate in the ovaries, or in the related areas of the fallopian tubes and the peritoneum. Some mutations (changes in genes) can raise your risk for ovarian cancer. Mutations in the breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2), and those associated with Lynch syndrome raise ovarian cancer risk.

 

Around 20,000 women get ovarian cancer each year in U.S. alone. However, it counts only 3% of all forms of cancer to women. We are noticing 11 new cases of ovarian cancer among 100,000 women in U.S. and 6.7 deaths.

 

Ovarian Cancer Drugs Market Outlook To 2025

 

Pricing Analysis

 

“Optimal Price Point (OPP) for Ovarian Cancer Drugs”

 

 

Estimated Average product/ service cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.

 

Due to the wide array of products available in the market, pricing, positioning, and sales channel optimization play a vital role in the success of a product. On an average, in the U.S., the ovarian cancer drugs are available at USD xxx- USD xxxx. However, the high-end products are available at much higher prices. The prices in emerging countries and developed countries vary significantly due to the difference in purchasing power and availability of latest products.

 

Ovarian Cancer Drugs Market by “Disease Type”

 

We have segmented the Ovarian Cancer Drugs market into Epithelial Ovarian Tumors, Ovarian Germ Cell Tumors, Ovarian Stromal Tumors, Primary Peritoneal Carcinoma. Ovarian epithelial tumors arise from the simple cuboidal surface epithelium of the ovary and account for 90% of all ovarian cancer. Epithelial ovarian cancer can be further segmented into serous, endometrioid, clear cell, mucinous and undifferentiated or unclassifiable. Ovarian germ cell tumor can cause swelling of the abdomen or vaginal bleeding after menopause. We are observing maximum development work on Epithelial Ovarian Cancer Drugs and will continue during the forecasting period.

 

Ovarian Cancer Drugs Market by “Treatment Categories”

 

We have segmented the Ovarian Cancer Drugs market by treatment into Chemotherapy, Radiation therapy, Immunotherapy, Autologous stem-cell transplantation, Targeted Therapy. We are observing newer biologic into immunotherapy shaping the Ovarian Cancer Drugs. Advancing novel therapeutic agents for the treatment of malignancy proving costly and lengthy process. Cost estimates for de novo drug discovery range from $500 million to $2 billion.

 

Ovarian Cancer Drugs Market by “Drug Class”

 

We have broadly segmented the market as PARP inhibitors, PD-L1 inhibitors, Angiogenesis Inhibitors and Others. Some of the major drugs are Olaparib (Astra Zeneca), Pembrolizumab, Bevacizumab (Avastin). However, we have considered following ovarian cancer drugs while determining the market size- Alkeran (Melphalan), Avastin (Bevacizumab), Bevacizumab, Carboplatin, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Dox-SL (Doxorubicin Hydrochloride Liposome), DOXIL (Doxorubicin Hydrochloride Liposome), Doxorubicin Hydrochloride Liposome, Evacet (Doxorubicin Hydrochloride Liposome), Gemcitabine Hydrochloride, Gemzar (Gemcitabine Hydrochloride), Hycamtin (Topotecan Hydrochloride), LipoDox (Doxorubicin Hydrochloride Liposome), Lynparza (Olaparib), Melphalan, Niraparib Tosylate Monohydrate, Olaparib, Paclitaxel, Rubraca (Rucaparib Camsylate), Rucaparib Camsylate, Taxol (Paclitaxel), Thiotepa, Topotecan Hydrochloride, Zejula (Niraparib Tosylate Monohydrate)

 

Ovarian Cancer Drugs Market by “Distribution Channel”

 

We have segmented the market based on distribution channel as Hospitals, Drug Store, Specialty Pharmacy, E-Pharmacy. Majority of products channelized through hospitals (Particularly Chemo, Surgery and Radiation). However, we are observing the increased role of specialized pharmacy and E-pharmacy in the distribution/ dispensation of treatment drugs. Patient education to increase compliance and Persistency plays a key role in the outcome. Many payors are linking reimbursement to the outcome.

 

Regional Segmentation

 

North America accounted for the maximum revenue share of over 70% in 2017 due to increased patient number, lifestyle followed by availability of treatment options, better reimbursement plan, and RND.  Followed by EU- Top 5 countries contribute $X.6 Billion in 2017 and expected to reach $x.5 Billion by 2023.

With changing lifestyle in developing countries and availability of treatment option, we are observing a rise in patient numbers in developing countries. However, these markets represent a minuscule percentage of the overall market.

 

“Competitive Landscape” and “Merger & Acquisition Insights”

 

The key market participants include AstraZeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceuticals, Kazia Therapeutics Ltd, Genentech Inc., Boehringer Ingelheim, and F. Hoffman-La Roche Ltd, Tesaro, and Clovis Oncology. The growing investment in research and development is driving the companies to innovate, stay market relevant and retain their share. Moreover, there are several startup companies working on stem cell and biologic research, and these companies are considered as strategic assets for merger and acquisition. Non-platinum based PARP inhibitors and VEGF inhibitors are changing the treatment paradigm for ovarian cancer significantly. We are observing a new drug development for ovarian cancer ONX-0801 is in Phase1. Some of the most notable transactions in the recent past include,

  • Novogen Limited, an oncology-focused biotechnology company, becomes Kazia Therapeutics Limited.
  • Tesaro’s acquisition with prospective bidder has diminished in event of news that rival drugs from AstraZeneca and Clovis are just as effective as Tesaro’s niraparib.

 

Market Segmentation

 

Ovarian Cancer Drugs Market by Disease Type (Revenue, Million, 2014 – 2025)

  • Epithelial Ovarian Tumors
  • Ovarian Germ Cell Tumors
  • Ovarian Stromal Tumors
  • Primary Peritoneal Carcinoma

 

Ovarian Cancer Drugs Market by Treatment Categories (Revenue, Million, 2014 – 2025)

  • Chemotherapy
  • Radiation therapy
  • Immunotherapy
  • Autologous stem-cell transplantation
  • Targeted Therapy

 

Ovarian Cancer Drugs Market by Drug Class (Revenue, Million, 2014 – 2025)

  • PARP inhibitors
  • PD-L1 inhibitors
  • Angiogenesis Inhibitors
  • Others

Ovarian Cancer Drugs Market by Distribution Channel (Revenue, Million, 2014 – 2025)

  • Hospitals
  • Drug Store
  • Specialty Pharmacy
  • E-Pharmacy

 

Ovarian Cancer Drugs Market Regional Outlook (Revenue, USD Million, 2014- 2025)

 

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Brazil
    • Mexico
    • Columbia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia

 

Ovarian Cancer Drugs Market, Ovarian Cancer Drugs Market Analytics, Ovarian Cancer Drugs Market Share, Ovarian Cancer Drugs Market Research, Ovarian Cancer Drugs Market Forecast, Ovarian Cancer Drugs Market Insight, Ovarian Cancer Drugs Market Trend, Ovarian Cancer Drugs Market Value,Ovarian Cancer Drugs Market Size, Ovarian Cancer Drugs Market Analysis, Ovarian Cancer Drugs Market Survey

Chapter 1 Methodology and Scope

  • Research Methodology
  • Research Scope & Assumptions
  • List of Data Sources

Chapter 2 Executive Summary

Chapter 3 Ovarian Cancer Drugs Market Overview

  • Global Disease Landscape
  • Global Healthcare Expenditure

Chapter 4 Ovarian Cancer Drugs Industry Outlook

  • Market Overview
  • Market Segmentation
  • Market Size and Growth Prospects
  • Leading Brand Dynamics
  • Key Market Drivers
    • Increasing patient base
    • Investment by Large Pharma for cancer research
    • Robust product pipeline
    • Increasing Collaboration
    • Increased diagnosis and early detection
    • Technological Advancements and newer drug approval
  • Key Market Challenges
    • Access barrier to high-cost drugs
    • Serious side effect to Cancer Drugs
  • Lack of Awareness and reimbursement plans in Emerging Countries
  • Key Opportunities Prioritized
  • Industry Analysis - Porter’s
  • Ovarian Cancer Drugs Market-PESTEL Analysis

Chapter 5: - Ovarian Cancer Drugs Market by “Disease Type” (USD Million)

  • Ovarian Cancer Drugs Market Landscape by Disease Type- 2017 & 2025
    • Epithelial Ovarian Tumors
  • Market Landscape Analysis, 2017-2025
    • Ovarian Germ Cell Tumors
  • Market Landscape Analysis, 2017-2025
    • Ovarian Stromal Tumors
  • Market Landscape Analysis, 2017-2025
    • Primary Peritoneal Carcinoma
  • Market Landscape Analysis, 2017-2025
 

Chapter 6: - Ovarian Cancer Drugs Market by “Treatment Categories” (USD Million)

  • Ovarian Cancer Drugs Market Landscape by Treatment Categories- 2017 & 2025
  • Chemotherapy
    • Market Landscape Analysis, 2017-2025
  • Radiation therapy
    • Market Landscape Analysis, 2017-2025
  • Immunotherapy
    • Market Landscape Analysis, 2017-2025
  • Autologous Stem Cell Transplantation
    • Market Landscape Analysis, 2017-2025

Chapter 7: - Ovarian Cancer Drugs Market by “Drug Class” (USD Million)

  • Ovarian Cancer Drugs Market Landscape by Drug Class- 2017 & 2025
  • PARP inhibitors
    • Market Landscape Analysis, 2017-2025
  • PD-L1 inhibitors
    • Market Landscape Analysis, 2017-2025
  • Angiogenesis Inhibitors
    • Market Landscape Analysis, 2017-2025
  • Others
    • Market Landscape Analysis, 2017-2025

Chapter 8: - Ovarian Cancer Drugs Market by “Distribution Channel” (USD Million)

  • Ovarian Cancer Drugs Market Landscape by Distribution Channel- 2017 & 2025
  • Hospitals
    • Market Landscape Analysis, 2017-2025
  • Drug Store
    • Market Landscape Analysis, 2017-2025
  • Specialty Pharmacy
    • Market Landscape Analysis, 2017-2025
  • E-Pharmacy
    • Market Landscape Analysis, 2017-2025

Chapter 9: Regional Market Outlook

Ovarian Cancer Drugs Market Landscape by Region- 2017
  • North America Market Landscape Analysis, 2017-2025 (USD Mn)
    • U.S. Market Landscape Analysis, 2017-2025
    • Canada Market Landscape Analysis-2017-2025
  • Europe Market Landscape Analysis, 2017-2025 (USD Mn)
    • UK Market Landscape Analysis, 2017-2025
    • Germany Market Landscape Analysis, 2017-2025
    • France Market Landscape Analysis, 2017-2025
    • Italy Market Landscape Analysis, 2017-2025
    • Spain Market Landscape Analysis, 2017-2025
  • Latin America Market Landscape Analysis, 2017-2025 (USD Mn)
    • Brazil Market Landscape Analysis, 2017-2025
    • Mexico Market Landscape Analysis, 2017-2025
    • Colombia Market Landscape Analysis, 2017-2025
  • Asia Pacific Market Landscape Analysis, 2017-2025 (USD Mn)
    • Japan Market Landscape Analysis, 2017-2025
    • China Market Landscape Analysis, 2017-2025
    • India Market Landscape Analysis, 2017-2025
  • Middle East & Africa Market Landscape Analysis, 2014-2025 (USD Mn)
    • Saudi Arabia Market Landscape Analysis, 2014-2025
    • South Africa Market Landscape Analysis, 2014-2025
 

Chapter 10: Pricing Analysis

  Optimal Price Points (OPP), Indifference price points (IPP) and Range of Acceptable Prices and (RAP) of leading brands by Region- 2017
  • North America Pricing Analysis (OPP, IPP, and RAP - 2017)
    • U.S. Pricing Analysis-2017
    • Canada Pricing Analysis-2017
  • Europe Pricing Analysis (OPP, IPP, and RAP - 2017)
    • UK Pricing Analysis-2017
    • Germany Pricing Analysis-2017
    • France Pricing Analysis-2017
    • Italy Pricing Analysis-2017
    • Spain Pricing Analysis-2017
  • Latin America Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Brazil Pricing Analysis-2017
    • Mexico Pricing Analysis-2017
    • Colombia Pricing Analysis-2017
  • Asia Pacific Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Japan Pricing Analysis-2017
    • China Pricing Analysis-2017
    • India Pricing Analysis-2017
  • Middle East Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Saudi Arabia Pricing Analysis-2017
    • South Africa Pricing Analysis-2017

Chapter 11: Ovarian Cancer Drugs Pipeline Analysis

  • Executive Summary
  • Late Stage Pipeline analysis
  • Key R&D trends

Chapter 12: Ovarian Cancer Drugs Merger & Acquisition Outlook

  • Factors driving M&A in Ovarian Cancer Drugs market
  • Key trends and future outlook

Chapter 13: Competitive Landscape

  • AstraZeneca
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Bristol Myers Squibb
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Hoffmann-La Roche Ltd
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Eli Lilly
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Tesaro
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • GlaxoSmithKline
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Boehringer Ingelheim
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Genentech Inc
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Clovis Oncology
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Janssen Pharmaceuticals
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Kazia Therapeutics Ltd
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
    List of Tables  
  • TABLE 1 Ovarian Cancer Drugs Market - Industry Snapshot & Key Buying Criteria, 2014 - 2025
  • TABLE 2 Global Ovarian Cancer Drugs Market, 2014 – 2025
  • TABLE 3 Global Ovarian Cancer Drugs Market Analysis by Product-2017
  • TABLE 4 Global Ovarian Cancer Drugs Market Analysis by Technology -2017
  • TABLE 5 Global Ovarian Cancer Drugs Market Analysis by Application-2017
  • TABLE 7 Global Ovarian Cancer Drugs Market Analysis by Geography-2017
  • TABLE 8 Global Ovarian Cancer Drugs Market Analysis by Leading Brands-2017
  • TABLE 9 Ovarian Cancer Drugs Market - Key market driver analysis
  • TABLE 10 Ovarian Cancer Drugs Market - Key market restraint analysis
  • TABLE 11 North America Market Ovarian Cancer Drugs Landscape Analysis, 2017-2025 (USD Mn)
  • TABLE 12U.S. Ovarian Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 13 Canada Ovarian Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 14 Europe Ovarian Cancer Drugs Market Landscape Analysis, 2017-2025 (USD Mn)
  • TABLE 15 U.K Ovarian Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 16 Germany Ovarian Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 17 France Ovarian Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 18 Italy Ovarian Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 19 Spain Ovarian Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 20 Latin America Ovarian Cancer Drugs Market Landscape Analysis, 2017-2025 (USD Mn)
  • TABLE 21 Brazil Ovarian Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 22 Mexico Ovarian Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 20 Colombia Ovarian Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 21 Asia Pacific Ovarian Cancer Drugs Market Landscape Analysis, 2017-2025 (USD Mn)
  • TABLE 22 Japan Ovarian Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 23 China Ovarian Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 24 India Ovarian Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 25 North America Pricing Analysis
  • TABLE 26 North America Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 27 U.S. Pricing Analysis-2017
  • TABLE 28 Canada Pricing Analysis-2017
  • TABLE 29 Europe Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 30 U.K Pricing Analysis-2017
  • TABLE 31 Germany Pricing Analysis-2017
  • TABLE 32 France Pricing Analysis-2017
  • TABLE 33 Italy Pricing Analysis-2017
  • TABLE 34 Spain Pricing Analysis-2017
  • TABLE 35 Latin America Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 36 Brazil Pricing Analysis-2017
  • TABLE 37 Mexico Pricing Analysis-2017
  • TABLE 38 Colombia Pricing Analysis-2017
  • TABLE 39 Asia Pacific Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 40 Japan Pricing Analysis-2017
  • TABLE 41 China Pricing Analysis-2017
  • TABLE 42 India Pricing Analysis-2017
  • TABLE 43 Middle East Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 44 Saudi Arabia Pricing Analysis-2017
  • TABLE 45 South Africa Pricing Analysis-2017
  List of Figures  
  • 1 Ovarian Cancer Drugs Market Segmentation
  • 2 Market Size & Growth Prospects
  • 3 Leading Brand Dynamics
  • 4 Penetration & Growth Prospects
  • 5 Industry Analysis – Porter’s
  • 6 Ovarian Cancer Drugs Market – PESTEL Analysis
  • 7 Ovarian Cancer Drugs Market Share by Product Type, 2017 & 2025
  • 7 Ovarian Cancer Drugs Market Share by Cell Type, 2017 & 2025
  • 7 Ovarian Cancer Drugs Market Share by Technique, 2017 & 2025
  • 7 Ovarian Cancer Drugs Market Share by Application, 2017 & 2025
  • 7 Ovarian Cancer Drugs Market Share by End-Use, 2017 & 2025
  • 10 Ovarian Cancer Drugs Market Share by Region, 2017 & 2025

Key Insights Addressed:  

  • Defining market size from 2014 to 2017.
  • Estimating market growth till 2025 and consequence market forecast.
  • Identifying market drivers, restraints & future opportunities and allowing decision-maker with a range of possible outcomes and the probabilities that will occur for any choice of action.
  • Market segments and regions that will drive or lead market growth.
  • Defining Optimal Price Point (OPP) which will be accepted and recommended by maximum customers.
  • A bird’s-eye view of competitive landscape and the key market players.
  • Key strategic growth driver adopted by market players. In-depth analysis of their strategies and implication on competition & growth.
    Key Findings:  
  • The global ovarian cancer drugs market was valued at $1.8 Billion in 2017 and is forecast to grow at a modest 29.2 % CAGR between 2018 and 2025, culminating in 2025 global sales of $X.5 Billion.
  • Around 20,000 women get ovarian cancer each year in U.S. alone. However, it counts only 3% of all forms of cancer to women. We are noticing 11 new cases of ovarian cancer among 100,000 women in U.S. and 6.7 deaths.
  • We have segmented the Ovarian Cancer Drugs market into Epithelial Ovarian Tumors, Ovarian Germ Cell Tumors, Ovarian Stromal Tumors, Primary Peritoneal Carcinoma.
  • The key market participants include AstraZeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceuticals, Kazia Therapeutics Ltd, Genentech Inc., Boehringer Ingelheim, and F. Hoffman-La Roche Ltd, Tesaro, and Clovis Oncology.

Ameri Research implies a unique methodology of published information and primary research to bring key insights to customer decision making process. Our analytics model helps us to understand the structured and unstructured information from various sources. Key steps involves in the process are as below-

    1. Analyzing Published Information- Access to large pool of paid and unpaid published information via different sources and analyzing market trend.
    2. Setting Foundation- Input from analysis of secondary sources set our foundation to market analysis and helps in setting the scope for further research. Setting the scope involves Ameri Research proprietary statistical model, discussion with industry leaders, internal brainstorming, key discussion pointers from various forums etc.
    3. Need Gap Analysis- Defining the gap between our scope and availability of information.
    4. KOL Panel Discussion- Focused Group Discussion with a structured discussion guide to fine tune the gap and deriving the factors driving/restraining the market trend.
    5. Quantitative Research- Sampling large number of industry players, Education/Research Institutes, Government bodies, NGOs, Individual acclaimed researchers and conducting the primary interview with a structured questionnaire.
    6. Data Triangulation- We apply bottom-up demand approach or top-down estimation or a combined approach to triangulate the data points.
    7. Analyst Comment- Each of our analysts carries large pool of experience from domain perspective and add their value which is directional in nature
global-aesthetic-dermatology-market

To request a free sample copy of this report, please complete the form below verified and secure

We offer complete free customization that addresses client’s need. This includes insights from primary market research and a 60-minute free analyst consultation post report purchase.

This website is secure and your personal details are safe. Privacy policy

Description

The global ovarian cancer drugs market was valued at $1.8 Billion in 2017 and is forecast to grow at a modest 29.2 % CAGR between 2018 and 2025, culminating in 2025 global sales of $X.5 Billion.

 

Ovarian cancer is a group of diseases that originate in the ovaries, or in the related areas of the fallopian tubes and the peritoneum. Some mutations (changes in genes) can raise your risk for ovarian cancer. Mutations in the breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2), and those associated with Lynch syndrome raise ovarian cancer risk.

 

Around 20,000 women get ovarian cancer each year in U.S. alone. However, it counts only 3% of all forms of cancer to women. We are noticing 11 new cases of ovarian cancer among 100,000 women in U.S. and 6.7 deaths.

 

Ovarian Cancer Drugs Market Outlook To 2025

 

Pricing Analysis

 

“Optimal Price Point (OPP) for Ovarian Cancer Drugs”

 

 

Estimated Average product/ service cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.

 

Due to the wide array of products available in the market, pricing, positioning, and sales channel optimization play a vital role in the success of a product. On an average, in the U.S., the ovarian cancer drugs are available at USD xxx- USD xxxx. However, the high-end products are available at much higher prices. The prices in emerging countries and developed countries vary significantly due to the difference in purchasing power and availability of latest products.

 

Ovarian Cancer Drugs Market by “Disease Type”

 

We have segmented the Ovarian Cancer Drugs market into Epithelial Ovarian Tumors, Ovarian Germ Cell Tumors, Ovarian Stromal Tumors, Primary Peritoneal Carcinoma. Ovarian epithelial tumors arise from the simple cuboidal surface epithelium of the ovary and account for 90% of all ovarian cancer. Epithelial ovarian cancer can be further segmented into serous, endometrioid, clear cell, mucinous and undifferentiated or unclassifiable. Ovarian germ cell tumor can cause swelling of the abdomen or vaginal bleeding after menopause. We are observing maximum development work on Epithelial Ovarian Cancer Drugs and will continue during the forecasting period.

 

Ovarian Cancer Drugs Market by “Treatment Categories”

 

We have segmented the Ovarian Cancer Drugs market by treatment into Chemotherapy, Radiation therapy, Immunotherapy, Autologous stem-cell transplantation, Targeted Therapy. We are observing newer biologic into immunotherapy shaping the Ovarian Cancer Drugs. Advancing novel therapeutic agents for the treatment of malignancy proving costly and lengthy process. Cost estimates for de novo drug discovery range from $500 million to $2 billion.

 

Ovarian Cancer Drugs Market by “Drug Class”

 

We have broadly segmented the market as PARP inhibitors, PD-L1 inhibitors, Angiogenesis Inhibitors and Others. Some of the major drugs are Olaparib (Astra Zeneca), Pembrolizumab, Bevacizumab (Avastin). However, we have considered following ovarian cancer drugs while determining the market size- Alkeran (Melphalan), Avastin (Bevacizumab), Bevacizumab, Carboplatin, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Dox-SL (Doxorubicin Hydrochloride Liposome), DOXIL (Doxorubicin Hydrochloride Liposome), Doxorubicin Hydrochloride Liposome, Evacet (Doxorubicin Hydrochloride Liposome), Gemcitabine Hydrochloride, Gemzar (Gemcitabine Hydrochloride), Hycamtin (Topotecan Hydrochloride), LipoDox (Doxorubicin Hydrochloride Liposome), Lynparza (Olaparib), Melphalan, Niraparib Tosylate Monohydrate, Olaparib, Paclitaxel, Rubraca (Rucaparib Camsylate), Rucaparib Camsylate, Taxol (Paclitaxel), Thiotepa, Topotecan Hydrochloride, Zejula (Niraparib Tosylate Monohydrate)

 

Ovarian Cancer Drugs Market by “Distribution Channel”

 

We have segmented the market based on distribution channel as Hospitals, Drug Store, Specialty Pharmacy, E-Pharmacy. Majority of products channelized through hospitals (Particularly Chemo, Surgery and Radiation). However, we are observing the increased role of specialized pharmacy and E-pharmacy in the distribution/ dispensation of treatment drugs. Patient education to increase compliance and Persistency plays a key role in the outcome. Many payors are linking reimbursement to the outcome.

 

Regional Segmentation

 

North America accounted for the maximum revenue share of over 70% in 2017 due to increased patient number, lifestyle followed by availability of treatment options, better reimbursement plan, and RND.  Followed by EU- Top 5 countries contribute $X.6 Billion in 2017 and expected to reach $x.5 Billion by 2023.

With changing lifestyle in developing countries and availability of treatment option, we are observing a rise in patient numbers in developing countries. However, these markets represent a minuscule percentage of the overall market.

 

“Competitive Landscape” and “Merger & Acquisition Insights”

 

The key market participants include AstraZeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceuticals, Kazia Therapeutics Ltd, Genentech Inc., Boehringer Ingelheim, and F. Hoffman-La Roche Ltd, Tesaro, and Clovis Oncology. The growing investment in research and development is driving the companies to innovate, stay market relevant and retain their share. Moreover, there are several startup companies working on stem cell and biologic research, and these companies are considered as strategic assets for merger and acquisition. Non-platinum based PARP inhibitors and VEGF inhibitors are changing the treatment paradigm for ovarian cancer significantly. We are observing a new drug development for ovarian cancer ONX-0801 is in Phase1. Some of the most notable transactions in the recent past include,

  • Novogen Limited, an oncology-focused biotechnology company, becomes Kazia Therapeutics Limited.
  • Tesaro’s acquisition with prospective bidder has diminished in event of news that rival drugs from AstraZeneca and Clovis are just as effective as Tesaro’s niraparib.

 

Market Segmentation

 

Ovarian Cancer Drugs Market by Disease Type (Revenue, Million, 2014 – 2025)

  • Epithelial Ovarian Tumors
  • Ovarian Germ Cell Tumors
  • Ovarian Stromal Tumors
  • Primary Peritoneal Carcinoma

 

Ovarian Cancer Drugs Market by Treatment Categories (Revenue, Million, 2014 – 2025)

  • Chemotherapy
  • Radiation therapy
  • Immunotherapy
  • Autologous stem-cell transplantation
  • Targeted Therapy

 

Ovarian Cancer Drugs Market by Drug Class (Revenue, Million, 2014 – 2025)

  • PARP inhibitors
  • PD-L1 inhibitors
  • Angiogenesis Inhibitors
  • Others

Ovarian Cancer Drugs Market by Distribution Channel (Revenue, Million, 2014 – 2025)

  • Hospitals
  • Drug Store
  • Specialty Pharmacy
  • E-Pharmacy

 

Ovarian Cancer Drugs Market Regional Outlook (Revenue, USD Million, 2014- 2025)

 

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Brazil
    • Mexico
    • Columbia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia

 

Ovarian Cancer Drugs Market, Ovarian Cancer Drugs Market Analytics, Ovarian Cancer Drugs Market Share, Ovarian Cancer Drugs Market Research, Ovarian Cancer Drugs Market Forecast, Ovarian Cancer Drugs Market Insight, Ovarian Cancer Drugs Market Trend, Ovarian Cancer Drugs Market Value,Ovarian Cancer Drugs Market Size, Ovarian Cancer Drugs Market Analysis, Ovarian Cancer Drugs Market Survey

Additional information

Price

Single User $5,650, Multiple User $8,650, Enterprise User $12,650